AI assistant
PARADIGM BIOPHARMACEUTICALS LIMITED.. — Call Transcript 2020
Apr 6, 2020
65527_rns_2020-04-06_55ea41e6-1c67-4c1b-be10-6a4bcd86d61f.pdf
Call Transcript
Open in viewerOpens in your device viewer
==> picture [137 x 74] intentionally omitted <==
PARADIGM BIOPHARMACEUTICALS LIMITED
ASX RELEASE 7 April 2020
PARADIGM TO HOST INVESTOR CALL TO DISCUSS US FDA REGULATORY PATHWAY, LATEST SAS REAL WORLD DATA AND CAPITAL RAISING PROCESS
Melbourne 7 April 2020, Paradigm Biopharmaceuticals Ltd (ASX: PAR): Paradigm is pleased to announce that it will host a conference call at 8:30am (AEST) Wednesday 8[th] April to discuss the recent minutes provided by the US FDA and guidance over the requirements for the Phase 3 clinical trial design and NDA submission. The company will also discuss the recent SAS data on 34 patients who have been treated using the Phase 3 material and measured with the same endpoints that will be used in the Phase 3 clinical trials.
Investors are encouraged to send through questions by 8:00pm (AEST) Tuesday 7[th] April, with the company collating questions sent and will endeavour to answer the most frequently asked.
Questions are to be submitted to [email protected]
Teleconference Details
You are invited to participate in a conference call held by Paradigm Biopharmaceuticals Limited CEO, Paul Rennie.
The call is scheduled for 8:30am (AEST) Wednesday 8[th] April. (US PST 3pm / EST 6 pm on Tueday 7[th] ; Hong Kong 6:30am ).
Dial-in Details
- - Register for the call at the following link: https://s1.c conf.com/diamondpass/10005685 invite.html
You will then be provided with the dial in number, the Passcode, and your unique access PIN. This information will also be emailed to you as a calendar invite.
To join the conference, simply dial the number in the calendar invite and enter the passcode followed by your PIN, and you will join the conference instantly .
To learn more please visit: www.paradigmbiopharma.com
FOR FURTHER INFORMATION PLEASE CONTACT: Simon White Director of Investor Relations Tel: +61 404 216 467 Paradigm Biopharmaceuticals Ltd ABN: 94 169 346 963 Level 15, 500 Collins St, Melbourne, VIC, 3000, AUSTRALIA Email : [email protected]